Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial
has served as a consultant for and/or received honoraria outside of the present study as an advisor/consultant for Tricog Health Inc, Lilly USA, Rivus, Cytokinetics, Roche Diagnostics, Sarfez Therapeutics, Edwards Lifesciences, Merck, Bayer, Novo Nordisk, Alleviant, and Axon Therapies
Option 2: Start With What's Already Approved and Proven Here's the clinical reality: tirzepatide, available as Zepbound with Ongoing Care, is already FDA-approved, has two-plus years of real-world safety data, and produces weight loss results that are genuinely impressive
These medications slow gastric emptying and reduce appetite, which can inadvertently decrease fluid intake while increasing the risk of dehydration through gastrointestinal symptoms like nausea, vomiting, and diarrhea
Do cravings come back
Pricing has shifted significantly through 2025 and into 2026, with new savings programs, coverage changes, and competitive pressures influencing costs
:max_bytes(150000):strip_icc()/what-medications-are-used-to-treat-binge-eating-5203479-notext-FINAL-23d015661f974a32b31410418e25c630.png)
US$ 26.04
:max_bytes(150000):strip_icc()/GuidelinesforEffectivelyDosingVyvanse-78c548e198ac4dac9d1f69f10e8857af.jpg)
US$ 28.06
US$ 29.12
US$ 28.32
US$ 22.49
US$ 21.53
